AMGEN INC·4

May 5, 8:12 PM ET

REESE DAVID M 4

4 · AMGEN INC · Filed May 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Amgen (AMGN) EVP David M. Reese Sells Shares to Cover Taxes

What Happened
David M. Reese, Executive Vice President & Chief Technology Officer of Amgen, disposed of 1,433 shares of AMGN on May 2, 2026 to satisfy tax withholding obligations. The disposals were in two lots — 746 shares and 687 shares — at $329.82 per share, for total proceeds of approximately $472,632. These disposals are reported as "Payment of exercise price or tax liability (F)," i.e., shares surrendered to cover taxes rather than open-market selling for investment purposes.

Key Details

  • Transaction date: May 2, 2026
  • Lots: 746 shares @ $329.82 = $246,046; 687 shares @ $329.82 = $226,586; total 1,433 shares for ~$472,632
  • Footnote: The shares include 442 Dividend Equivalents (DEs) credited to unvested RSUs under Amgen’s equity plan and paid out in shares per the vesting schedule (F1)
  • Transaction type code: F (payment of exercise price or tax liability / tax withholding via share surrender)
  • Shares owned after the transaction: not specified in the provided filing excerpt
  • Filing: Accession filed May 5, 2026 (reporting period May 2, 2026)

Context
This was a tax-withholding share surrender (often called a "sell to cover" or share-for-tax) tied to equity awards and dividend equivalents, not an open-market sale intended as market timing. Such transactions are common for executives when RSUs vest or dividend equivalents are paid and generally reflect tax settlement rather than a directional bet on the stock.

Insider Transaction Report

Form 4
Period: 2026-05-02
REESE DAVID M
EVP & Chief Technology Officer
Transactions
  • Tax Payment

    Common Stock

    2026-05-02$329.82/sh746$246,04641,041 total
  • Tax Payment

    Common Stock

    [F1]
    2026-05-02$329.82/sh687$226,58640,354 total
Footnotes (1)
  • [F1]These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Signature
/s/ David M. Reese|2026-05-04

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT